Novel cell and immune engagers in optimizing tumor specific immunity post autologous transplant in multiple myeloma

Significant advances in the management of multiple myeloma (MM) during the last few decades have resulted in better patient outcomes, yet MM remains a largely incurable disease. Incorporation of immunomodulatory agents (Imids), proteasome inhibitors and monoclonal antibodies into standard combination therapies is well established and recently novel cellular therapies have been rapidly gaining their place in the management of MM.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research